文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

识别可从多粘菌素B血液灌流中获益的脓毒性休克人群:一项采用限制性立方样条回归模型的前瞻性队列研究

Identifying Septic Shock Populations Benefitting From Polymyxin B Hemoperfusion: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model.
PubMed 文献 · Shock · 2020-01-01
一句话结论多粘菌素B血液灌流整体未降低脓毒性休克患者住院死亡率,但高龄且病情严重度高的亚组可能获益。

该前瞻性全国队列纳入日本59个ICU连续成人严重脓毒症(Sepsis-2)患者,比较多粘菌素B血液灌流(PMX-HP)与未使用者的住院死亡率。多变量Cox回归显示PMX-HP整体与死亡率改善无关;APACHE II评分交互作用P=0.189,SOFA评分交互作用P=0.413。三向交互分析显示,仅在高龄且两种评分均属最严重亚组的脓毒性休克患者中,PMX-HP组风险 hazard 受抑;而高龄但两种评分均属较低严重度亚组者风险 hazard 升高。结论提示PMX-HP可能仅对高龄且病情更重的有限人群有益。

要点

  • 整体脓毒性休克人群中,PMX-HP与住院死亡率改善无关(多变量Cox回归)。
  • APACHE II评分对PMX-HP效应的修饰作用P for interaction=0.189,SOFA评分P for interaction=0.413。
  • 三向交互分析显示,高龄且APACHE II与SOFA均属最严重亚组的脓毒性休克患者中,PMX-HP组风险 hazard 受抑。
  • 高龄但两种评分均属较低严重度亚组者,PMX-HP组风险 hazard 升高。
  • PMX-HP可能仅对高龄且病情更重的有限人群有益,整体人群未见获益。

适用人群与场景

  • 日本59个ICU连续成人严重脓毒症(Sepsis-2)患者,最终队列741例(92例接受PMX-HP,625例未接受)。

研究设计与关键结果

  • 前瞻性全国队列,741例脓毒症患者(92例接受PMX-HP,625例未接受),多变量Cox比例风险回归显示PMX-HP整体与住院死亡率改善无关。
  • APACHE II评分对PMX-HP效应的交互作用P=0.189,SOFA评分交互作用P=0.413。
  • 三向交互分析显示,仅在高龄且APACHE II与SOFA均属最严重亚组的脓毒性休克患者中,PMX-HP组较对照组风险 hazard 受抑;高龄但两种评分均属较低严重度亚组者风险 hazard 升高。

证据类型、等级与局限

  • 证据类型:前瞻性全国队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,PMX-HP虽未降低整体脓毒性休克患者住院死亡率,但可能对高龄且病情更重的有限人群有益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Polymyxin B hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that removes circulating endotoxin. However, PMX-HP has seldom achieved expectations in randomized trials targeting nonspecific overall sepsis patients. If used in an optimal population, PMX-HP may be beneficial. This study aimed to identify the optimal population for PMX-HP in patients with septic shock.

METHODS: We used a prospective nationwide cohort targeting consecutive adult patients with severe sepsis (Sepsis-2) in 59 intensive care units in Japan. Associations between PMX-HP therapy and in-hospital mortality were assessed using multivariable Cox proportional hazard regression models. To identify best targets for PMX-HP, we developed a non-linear restricted cubic spline model including two-way interaction term (treatment × Acute Physiology and Chronic Health Evaluation [APACHE] II score/Sequential Organ Failure Assessment [SOFA] score) and three-way interaction term (treatment × age × each score).

RESULTS: The final study cohort comprised 741 sepsis patients (92 received PMX-HP, 625 did not). Cox proportional hazards regression model adjusted for the covariates suggested no association between PMX-HP therapy and improved mortality overall. Effect modification of PMX-HP by APACHE II score was statistically significant (P for interaction = 0.189) but non-significant for SOFA score (P for interaction = 0.413). Three-way interaction analysis revealed suppressed risk hazard in the PMX-HP group versus control group only in septic shock patients with high age and in the most severe subset of both scores, whereas increased risk hazard was observed in those with high age but in the lower severity subset of both scores.

CONCLUSIONS: Our results suggested that although PMX-HP did not reduce in-hospital mortality among overall septic shock patients, it may benefit a limited population with high age and higher disease severity.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Nakata H, Yamakawa K, Kabata D, et al. Identifying Septic Shock Populations Benefitting From Polymyxin B Hemoperfusion: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model. Shock. 2020. PMID: 32195922. doi:10.1097/SHK.0000000000001533

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。